Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential
Molecules · 20.11.2024 · 29 (22) · 5471
DOI: 10.3390/molecules29225471 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 20.11.2024. Verfasst von Shijia Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China. Hauptthemen laut MEDLINE: Cannabinoids. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cannabigerol (CBG), a non-psychoactive cannabinoid found in cannabis, has emerged as a promising therapeutic agent with a diverse range of potential applications. Unlike its well-known counterpart tetrahydrocannabinol (THC), CBG does not induce intoxication, making it an attractive option in the clinic. Recent research has shed light on CBG’s intriguing molecular mechanisms, highlighting its potential to modulate multiple physiological processes. This review delves into the current understanding of CBG’s molecular interactions and explores its therapeutic power to alleviate various conditions, including cancer, metabolic, pain, and inflammatory disorders, amongst others. We discuss how CBG interacts with the endocannabinoid system and other key signaling pathways, such as CB1, CB2, TPR channels, and α2-adrenoceptor, potentially influencing inflammation, pain, neurodegeneration, and other ailments. Additionally, we highlight the ongoing research efforts aimed at elucidating the full spectrum of CBG’s therapeutic potential and its safety profile in clinical settings. Through this comprehensive analysis, we aim to provide a deeper understanding of CBG’s role in promoting human health and pave the way for future research endeavors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China.
- Department of Biomedical Science, Cedars-Sinai Medical Center, Cedars-Sinai Cancer Institute, Los Angeles, CA 90067, USA.
- Department of Diabetes Complications and Metabolism, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
- South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
- School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
ORCID-Profile: Naseeb Kaur Malhi, Ziwei Zhou, Ruiheng Wang, Jiangling Peng, Honggen Wang
Zitieren
APA
Li, S., Li, W., Malhi, N. K., Huang, J., Li, Q., Zhou, Z., Wang, R., Peng, J., Yin, T., & Wang, H. (2024). Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. Molecules, 29(22), 5471. https://doi.org/10.3390/molecules29225471
Vancouver
Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, et al. Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential. Molecules. 2024;29(22):5471. doi:10.3390/molecules29225471
BibTeX
@article{Li2024,
author = {Li, Shijia and Li, Weini and Malhi, Naseeb Kaur and Huang, Junwei and Li, Quanqi and Zhou, Ziwei and Wang, Ruiheng and Peng, Jiangling and Yin, Tong and Wang, Honggen},
title = {Cannabigerol (CBG): A Comprehensive Review of Its Molecular Mechanisms and Therapeutic Potential},
journal = {Molecules},
year = {2024},
volume = {29},
number = {22},
pages = {5471},
doi = {10.3390/molecules29225471}
}
EUVIMED